1887
  1. Home
  2. Eurosurveillance
  3. Volume 23, Issue 7, 15/Feb/2018
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20–54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2018.23.7.18-00057
2018-02-15
2024-12-22
/content/10.2807/1560-7917.ES.2018.23.7.18-00057
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/23/7/eurosurv-23-7-1.html?itemId=/content/10.2807/1560-7917.ES.2018.23.7.18-00057&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Weekly influenza update, week 5, January 2018. Stockholm: ECDC. [Accessed 12 Feb 2018]. Available from: https://ecdc.europa.eu/en/publications-data/weekly-influenza-update-week-5-january-2018
  2. Sistema de Vigilancia de la Gripe en España. Informe semanal de Vigilancia de la Gripe en España. Semana 5/2018 N° 531. [Weekly report of the influenza surveillance system in Spain 5/2018. No 531]. Madrid: Instituto de Salud Carlos III; 8 February 2018. Spanish. Available from: http://vgripe.isciii.es/documentos/20172018/boletines/grn052018.pdf
  3. Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill. 2017;22(43):17-00707.  https://doi.org/10.2807/1560-7917.ES.2017.22.43.17-00707  PMID: 29090681 
  4. Wise J. Trivalent flu vaccine won’t protect against influenza B strain predominantly circulating. BMJ. 2018;360:k78.  https://doi.org/10.1136/bmj.k78  PMID: 29305384 
  5. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85.  https://doi.org/10.1093/cid/ciu680  PMID: 25270645 
  6. Castilla J, Navascués A, Casado I, Díaz-González J, Pérez-García A, Fernandino L, et al. , Primary Health Care Sentinel Network And The Network For Influenza Surveillance In Hospitals Of Navarre. Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis. Euro Surveill. 2017;22(7):30465.  https://doi.org/10.2807/1560-7917.ES.2017.22.7.30465  PMID: 28230523 
  7. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Wkly Epidemiol Rec. 2017;92(11):117-28. PMID: 28303704 
  8. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec. 2016;91(10):121-32. PMID: 26971356 
  9. Aguilar I, Reyes M, Martínez-Baz I, Guevara M, Albéniz E, Belza M, et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill. 2012;17(17):20154.  https://doi.org/10.2807/ese.17.17.20154-en  PMID: 22551499 
  10. Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill. 2018;23(5):1800035.  https://doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035  PMID: 29409570 
  11. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40.  https://doi.org/10.1093/infdis/jiu647  PMID: 25406334 
  12. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37.  https://doi.org/10.1093/infdis/jiu048  PMID: 24446529 
  13. Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis. 2012;205(12):1858-68.  https://doi.org/10.1093/infdis/jis283  PMID: 22492921 
  14. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25(15):2842-51.  https://doi.org/10.1016/j.vaccine.2006.10.002  PMID: 17081662 
  15. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-2016 season in Canada. J Infect Dis. 2017;216(12):1487-500.  https://doi.org/10.1093/infdis/jix526  PMID: 29029166 
  16. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010;28(46):7381-8.  https://doi.org/10.1016/j.vaccine.2010.09.010  PMID: 20851086 
Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Ana+Navascu%C3%A9s&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Navascués Ana</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Alejandra+P%C3%A9rez-Garc%C3%ADa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pérez-García Alejandra</a>, <a href="/search?value1=Aitziber+Aguinaga&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Aguinaga Aitziber</a>, <a href="/search?value1=Guillermo+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Guillermo</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Carmen+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Carmen</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Primary+Health+Care+Sentinel+Network&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Primary Health Care Sentinel Network</a>, <a href="/search?value1=Network+for+Influenza+Surveillance+in+Hospitals+of+Navarre&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Network for Influenza Surveillance in Hospitals of Navarre</a></span>. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. <a href="/content/ecdc">Euro Surveill.</a> 2018;23(7):pii=18-00057. <a href="https://doi.org/10.2807/1560-7917.ES.2018.23.7.18-00057" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2018.23.7.18-00057</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 05 Feb 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 15 Feb 2018 </span> </p>
/content/10.2807/1560-7917.ES.2018.23.7.18-00057
/content/10.2807/1560-7917.ES.2018.23.7.18-00057
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error